Your browser doesn't support javascript.
loading
Evaluating IL-21 as a Potential Therapeutic Target in Crohn's Disease.
Holm, Thomas Lindebo; Tornehave, Ditte; Søndergaard, Henrik; Kvist, Peter Helding; Sondergaard, Bodil-Cecilie; Hansen, Lene; Hermit, Mette Brunsgaard; Holgersen, Kristine; Vergo, Sandra; Frederiksen, Klaus Stensgaard; Haase, Claus; Lundsgaard, Dorthe.
Afiliación
  • Holm TL; Global Research, Novo Nordisk A/S, Maaloev, Denmark.
  • Tornehave D; Global Research, Novo Nordisk A/S, Maaloev, Denmark.
  • Søndergaard H; Global Research, Novo Nordisk A/S, Maaloev, Denmark.
  • Kvist PH; Global Research, Novo Nordisk A/S, Maaloev, Denmark.
  • Sondergaard BC; Global Research, Novo Nordisk A/S, Maaloev, Denmark.
  • Hansen L; Global Research, Novo Nordisk A/S, Maaloev, Denmark.
  • Hermit MB; Global Research, Novo Nordisk A/S, Maaloev, Denmark.
  • Holgersen K; Novo Nordisk LIFE In Vivo Pharmacology Centre, Frederiksberg, Denmark.
  • Vergo S; Global Research, Novo Nordisk A/S, Maaloev, Denmark.
  • Frederiksen KS; Global Research, Novo Nordisk A/S, Maaloev, Denmark.
  • Haase C; Global Research, Novo Nordisk A/S, Maaloev, Denmark.
  • Lundsgaard D; Global Research, Novo Nordisk A/S, Maaloev, Denmark.
Gastroenterol Res Pract ; 2018: 5962624, 2018.
Article en En | MEDLINE | ID: mdl-29849593
ABSTRACT
BACKGROUND AND

AIM:

Interleukin-21 (IL-21) is primarily a T cell-derived cytokine; it is upregulated in patients with Crohn's Disease (CD) and could be a potential new therapeutic target in CD.

METHODS:

In human material, IL-21 and IL-21R expression was investigated by in situ hybridization (ISH) and immunohistochemistry (IHC) in noninflammatory bowel disease (non-IBD) controls and patients with CD. The pathologic role of IL-21 was examined in murine models of T cell-dependent and T cell-independent colitis, either with a neutralizing monoclonal antibody against IL-21 or with the transfer of CD4+CD45RBhighIL-21R-/- T cells. Colonic pathology was examined by endoscopy, histopathology, IHC, ELISA, and Luminex.

RESULTS:

In the human intestine, IL-21 and IL-21R mRNA and protein-expressing cells were observed in the mucosa, in lymphoid aggregates of submucosa in non-IBD controls, and in lymphoid aggregates of muscularis externa in patients with CD. IL-21 expression was most abundant in germinal centers (GCs) of the lymphoid aggregates, and IL-21R expression assessed semiquantitatively, was significantly higher in patients with CD compared to non-IBD controls. Following prophylactic and interventive anti-IL-21 mAb treatment in the adoptive transfer (AdTr) model, clinical and pathological parameters were significantly reduced. The most persistent finding was a reduction in colonic infiltrating neutrophils. As well, Rag2-/- mice receiving CD4+CD45RBhighIL-21R-/- T cells developed less severe colitis compared to Rag2-/- mice receiving CD4+CD45RBhighIL-21R+/+ T cells. No effect of reduced IL-21 signalling was observed in T cell-independent colitis.

CONCLUSION:

Our study shows that patients with CD have significant expression of IL-21 and IL-21R in the gut. As well, we show that neutralization of IL-21 in experimental T cell-driven colitis is associated with a reduction in clinical and pathological findings. This amelioration seems to be associated with a reduction in colon-infiltrating neutrophils.

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Gastroenterol Res Pract Año: 2018 Tipo del documento: Article País de afiliación: Dinamarca

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Gastroenterol Res Pract Año: 2018 Tipo del documento: Article País de afiliación: Dinamarca